Defender Pharmaceuticals

The motion sickness gel stopped after an FDA rejection, according to a pharmaceutical trade report. In 2025 the company received an exclusive licence to develop dimethyl trisulfide, an injectable cyanide antidote developed by the US Army Medical Research Institute of Chemical Defense, which a Defense Health Agency article described as reaching a milestone in May 2025.

It is preparing submissions to the FDA for clinical studies. A federal laboratory consortium notice records the intent to grant the licence.

Funding and contract values were not found.

Privately held; investors listed on Dealroom (not read in detail)

Parent: none (publicly listed)

• https://defenderpharma.com/
• https://www.pharmaceutical-technology.com/news/defenders-plans-for-motion-sickness-nasal-gel-stop-with-fda-rejection/
• https://www.dha.mil/News/2025/05/19/13/42/New-Cyanide-Countermeasure-Developed-at-USAMRICD-Reaches-Crucial-Milestone
• https://federallabs.org/flc-business/notice-of-intent-to-license/intent-to-grant-an-exclusive-license-for-u-s-government-co-owned-invention
• https://app.dealroom.co/companies/defender_pharmaceuticals

• Funding, investors and contract values: not read.
• Whether the licence has been finalised and its date: the notice was an intent to grant.
• Clinical status: not found.